Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited has appointed Lyn Cobley, a seasoned leader in the financial services industry, to its Board of Directors. This strategic move follows the recent FDA approval of RYONCIL and aims to bolster Mesoblast’s commercialization efforts and expansion into new indications for prevalent diseases. Cobley’s extensive experience in corporate finance and governance is expected to enhance Mesoblast’s strategic leadership as it continues to develop and commercialize its cell therapy products.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company specializes in mesenchymal lineage cell therapy technology, which addresses severe inflammation by releasing anti-inflammatory factors. Mesoblast’s flagship product, RYONCIL, is FDA-approved for treating steroid-refractory acute graft versus host disease in pediatric patients and is being developed for other inflammatory diseases. The company has established commercial partnerships in Japan, Europe, and China and holds a robust intellectual property portfolio.
YTD Price Performance: -31.82%
Average Trading Volume: 400,962
Technical Sentiment Signal: Sell
Current Market Cap: $1.46B
See more data about MSB stock on TipRanks’ Stock Analysis page.